El paradigma dels metal·lacarborans: ús dels clústers en tractaments de càncer, contra bacteris resistents i en catàlisi verda
Miquel Nuez Martínez, Inorganic Materials & Catalysis (LMI) group at ICMAB-CSIC
Date: Friday, 25 November 2022
Time: 10:30 am
Venue: Facultat de Ciències UAB, seminari de Química (C7/003). Register here to attend online by Zoom.
Application of metallabis(dicarbollides) as drugs is a topic on the rise. First, physico-chemical studies of six metallabis(dicarbollides) were carried out, these studies helped the knowledge deepening in their interaction with biomolecules, highlighting interaction with proteins, DNA, sugars and artificial lipidic membrane crossing.
These interactions were also observed in vitro at ALBA synchrotron; and in vivo, using C.elegans, which helped with their later application as drugs for cancer multitherapies: chemo-, radiotherapy and boron exclusive BNCT and PBFR, which was tested for the first time. Metallabis(dicarbollides) were also successful acting as small molecule drugs against resistant bacteria and yeasts.
Finally, seeing the improvement provided by doping PEDOT with cobaltabis(dicarbollide), its use as catalyst for water oxidation has been proposed.
- Clara Viñas i Teixidor, Inorganic Materials & Catalysis (LMI) group at ICMAB-CSIC
- President: Ramón Macías Maza, Universidad de Zaragoza, Espanya
- Secretary: Gonzalo Guirado López, UAB
- Vocal: Anna Rosell Novel, Vall d'Hebron institut de Recerca (VHIR)
University: Universitat Autònoma de Barcelona (UAB)
PhD Programme: Chemistry
Scheme of a metallabis(dicarbollide) and their applications in that thesis: biomolecule interaction, anticancer multitherapies, as antibiotics and as dopant for COPs for green catalysis. | Miqul Nuez, ICMAB, CSIC